布地奈德福莫特罗吸入治疗对慢阻肺合并肺癌稳定期患者的疗效研究

Efficacy Study of Inhaled Therapy with Symbicort Turbulaler in the Treatment of Patients with Lung Cancer Complicated with Chronic Obstructive Pulmonary Disease

目的:探讨布地奈德福莫特罗吸入治疗对慢阻肺合并肺癌稳定期患者的疗效。方法:将医院呼吸内科2016年4月至2017年6月期间收治的78例COPD合并肺癌患者作为本次研究对象,按照随机对照的原则分为观察组(39例)和对照组(39例)。对照组给予肺癌、COPD稳定期常规基础治疗和对症治疗,观察组在此基础上给予布地奈德福莫特罗粉吸入剂吸入治疗,1吸/次,2次/d,早晚各1次,规律治疗3个月,治疗期间定期进行随访。结果:治疗前两肺功能指标、炎性因子指标和生活质量评分比较无差异(P>0.05)。治疗后两组FEV1%、FEV1/FVC指标均有明显的提高,其中观察组明显高于对照组(P<0.05);两组IL-6、IL-8指标均有明显的降低,其中观察组明显低于对照组(P<0.05);两组呼吸症状、活动受限和疾病影响和SGRQ总分均有明显降低,其中观察组明显低于对照组(P<0.05)。治疗随访期间,观察组不良反应发生率为17.95%,对照组不良反应发生率为12.82%,差异无统计学意义(P>0.05)。结论:布地奈德福莫特罗吸入治疗能够显著改善慢阻肺合并肺癌稳定期患者肺功能和生活质量,值得推广。

Objective： To explore the effect of inhaled therapy with symbicort turbulaler in the treatment of patients with lung cancer complicated with chronic obstructive pulmonary disease. Methods： 78 cases of COPD patients with lung cancer treated in the hospital respiratory department in April 2016 to June 2017 were selected as the study objects. According to the principle of random control,the patients were divided into the observation group（39 cases） and the control group（39 cases）.The control group was given conventional basic treatment and symptomatic treatment for lung cancer and COPD stable period. On the basis of this,the observation group was given inhaled therapy with symbicort turbulaler.1 intake/time,2 times/d,1 times in the morning and evening,regular treatment for 3 months,regular follow-up during treatment. Results： There was no difference in the two lung function indexes,inflammatory factors and quality of life scores before treatment（P0.05）. After treatment,the FEV1% and FEV1/FVC indexes of the two groups were significantly improved,and the observation group was significantly higher than the control group（P 0.05）. IL-6 and IL-8 indicators of two groups were significantly reduced.The observation group was significantly lower than the control group（P 0.05）. During the follow-up period,the incidence of adverse reactions in the observation group was 17.95%,and the incidence of adverse reactions in the control group was 12.82%,the difference was not statistically significant（P 0.05）. Conclusion： Inhaled therapy with symbicort turbulaler can significantly improve lung function and quality of life in patients with chronic obstructive pulmonary disease with stable stage of lung cancer,and is worthy of promotion.